Roche

SoftGenetics, 454 Life Sciences promote next-gen sequencing software

Monday, May 14, 2012 01:19 PM

SoftGenetics and 454 Life Sciences, a Roche subsidiary, have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems with the sequencing data analysis options provided by SoftGenetics’ NextGENe software.

More... »


Roche will not extend offer for Illumina

Wednesday, April 18, 2012 11:00 AM

Roche has decided not to extend its tender offer for Illumina, based on preliminary estimates indicating the re-election of the incumbent directors of Illumina. Roche’s cash tender offer is due to expire on April 20, 2012 at 6 p.m. EST.

More... »


Seattle Genetics, Millennium, Ventana collaborate on companion diagnostic test for Adcetris

Friday, April 13, 2012 12:37 PM

Seattle Genetics and Millennium, a subsidiary of Takeda Pharmaceutical, have formed a collaboration with Ventana Medical Systems, a member of the Roche Group, through which Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with Adcetris based on CD30 expression levels in their tissue specimens.

More... »

Roche disappointed with ISS recommendation

Monday, April 9, 2012 09:19 AM

The Institutional Shareholder Services (ISS) has recommended that shareholders of Illumina vote against the election of Roche’s independent director nominees to Illumina’s board of directors.

More... »

Burrill wraps up life sciences industry for Q1 2012

Wednesday, April 4, 2012 03:00 PM

Burrill & Company, a diversified global financial services firm focused on the life sciences industry, has identified more than $2.6 billion in expected funding through nine translational research and early-stage initiatives announced since the end of February.

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Roche increases offer for Illumina $51 per share

Friday, March 30, 2012 09:17 AM

Roche has increased its offer price for all outstanding publicly-held shares of Illumina, $51 per share in cash. All other terms and conditions of the tender offer remain unchanged.

More... »

Academic-industry collaboration seeks new drugs, treatments for autism

Monday, March 19, 2012 02:41 PM

An international consortium of scientists led by Roche, King's College London and Autism Speaks is collaborating on one of the largest ever academic-industry research projects, to find new methods for the development of drugs for autism spectrum disorder (ASD), which affects 1% of children worldwide.

More... »

ICON, Roche in technology partnership

Tuesday, March 6, 2012 01:27 PM

Global CRO ICON has been selected by Roche as its technology partner for storing and managing medical images collected during the company’s clinical research programs.

More... »

Ventana receives FDA clearance for Ki-67 (30-9) image analysis

Tuesday, March 6, 2012 06:06 AM

The FDA has granted Ventana Medical Systems, a member of the Roche Group, 510(k) clearance for its Ventana Companion Algorithm Ki-67 (30-9) image analysis application used with the Ventana iScan Coreo Au scanner running Virtuoso software.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs